Evolution of the treatment paradigm for maximum medical therapy in glaucoma

References

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
   PubMed Web of Science ®Google Scholar
• Wang K, Xu L, Yuan Z, et al. Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China. BMC Ophthalmol. 2014;14:21.
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® guidelines. Primary open-angle glaucoma; [cited 2018 Mar 8]. Available from: https://www.aao.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp-2015
   Google Scholar
• Sultan MB, Mansberger SL, Lee PP. Understanding the importance of IOP variables in glaucoma: a systematic review. Surv Ophthalmol. 2009;54:643–662.
   PubMed Web of Science ®Google Scholar
• Nguyen QH. Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence. 2014;8:853–864.
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713.
   PubMed Web of Science ®Google Scholar
• Schwartz G, Burk C, Bennett T, et al. Adherence and persistence with glaucoma therapy: brimonidine/timolol versus dorzolamide/timolol and various two-bottle combinations. J Clin Exp Ophthalmol. 2012;3:1–6.
   Google Scholar
• Soltau JB, Zimmerman TJ. Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol. 2002;47(suppl 1):S2–5.
   PubMedGoogle Scholar
• Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol. 2004;137:S13–S16.
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598–606.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Quigley HA, Gelb L. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Group (GAPS). Invest Ophthalmol Vis Sci. 2007;48:5052–5057.
   PubMed Web of Science ®Google Scholar
• Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically: the Travatan Dosing Aid Study. Ophthalmology. 2009;116:191–199.
   PubMed Web of Science ®Google Scholar
• Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology. 2005;112:953–961.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008;115:1320–1327.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Okeke CO, Jampel HD, et al. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology. 2009;116:1097–1105.
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, et al. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21:410–414.
   PubMed Web of Science ®Google Scholar
• Kholdebarin R, Campbell RJ, Jin YP, et al. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43:454–461.
   PubMed Web of Science ®Google Scholar
• Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–436.
   PubMed Web of Science ®Google Scholar
• Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–540.
   PubMed Web of Science ®Google Scholar
• Hermann MM, Bron AM, Creuzot-Garcher CP, et al. Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring. J Glaucoma. 2011;20:502–508.
   PubMed Web of Science ®Google Scholar
• Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011;59:S93–96.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–719.
   PubMed Web of Science ®Google Scholar
• Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130:832–833.
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1–9.
   PubMedGoogle Scholar
• Aptel F, Chiquet C, Romanet JP. Intraocular pressure-lowering combination therapies with prostaglandin analogues. Drugs. 2012;72:1355–1371.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29:382–389.
   PubMed Web of Science ®Google Scholar
• Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging. 2007;24:1007–1016.
   PubMed Web of Science ®Google Scholar
• Kalouda P, Keskini C, Anastasopoulos E, et al. Achievements and limits of current medical therapy of glaucoma. Dev Ophthalmol. 2017;59:1–14.
   PubMedGoogle Scholar
• Aihara M, Otani S, Kozaki J, et al. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma. 2012;21:60–64.
   PubMed Web of Science ®Google Scholar
• Goldberg I, Graham SL, Crowston JG, et al. Clinical audit examining the impact of benalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocula surface disease. Clin Exp Ophthalmol. 2015;43:214–220.
   PubMed Web of Science ®Google Scholar
• Baiza-Duran LM, Alvarez-Delgado J, Contreras-Rubio AY, et al. The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial. Ann Ophthalmol (Skokie). 2009;41:174–178.
   PubMedGoogle Scholar
• Baiza-Duran LM, Llamas-Moreno JF, Ayala-Barajas C. Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2012;6:1051–1055.
   PubMedGoogle Scholar
• Garcia-Lopez A, Paczka JA, Jimenez-Roman J, et al. Efficacy andtolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. BMC Ophthalmol. 2014;14:161.
   PubMed Web of Science ®Google Scholar
• Juncal VR, Abdo Jorge F, Paranhos A Jr., et al. Carbonic anhydrase inhibitors as fourth drug in primary glaucomas: is it worth it? Can J Ophthalmol. 2015;50:297–301.
   PubMed Web of Science ®Google Scholar
• Neelakantan A, Vaishnav HD, Iyer SA, et al. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004;13:130–136.
   PubMed Web of Science ®Google Scholar
• Bro T, Linden C. The more, the better? The usefulness of brimonidine as the fourth antiglaucoma eye drop. J Glaucoma. 2018;27:643–646.
   PubMed Web of Science ®Google Scholar
• Hartleben C, Parra JC, Batoosingh A, et al. A masked, randomized, phase 3 comparison of triple fixed-combination bimatoprost/brimonidine/timolol versus fixed-combination brimonidine/timolol for lowering intraocular pressure. J Ophthalmol. 2017;2017:4586763.
   Web of Science ®Google Scholar
• Fechtner RD, Harasymowycz P, Nixon DR, et al. Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost. Clin Ophthalmol. 2011;5:945–953.
   PubMedGoogle Scholar
• Goldberg I, Crowston JG, Jasek MC, et al. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy. J Glaucoma. 2012;21:55–59.
   PubMed Web of Science ®Google Scholar
• Hollo G, Kothy P. Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma. Curr Med Res Opin. 2008;24:1755–1761.
   PubMed Web of Science ®Google Scholar
• Feldman RM, Katz G, McMenemy M, et al. A randomized trial of fixed-dose combination brinzolamide 1%/brimonidine 0.2% as adjunctive therapy to travoprost 0.004. Am J Ophthalmol. 2016;165:188–197.
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Myers JS, Hubatsch DA, et al. Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial. Eye (Lond). 2016;30:1343–1350.
   PubMed Web of Science ®Google Scholar
• Topouzis F, Nicolela M, Lerner F, et al. The additive intraocular pressurelowering effect of twice-daily brinzolamide 1%/brimonidine 0.2% fixed-dose combination in patients with glaucoma. Presented at: World Ophthalmology Congress; 2018 June 17; Barcelona, Spain.
   Google Scholar
• Konstas AG, Quaranta L, Bozkurt B, et al. 24-h efficacy of glaucoma treatment options. Adv Ther. 2016;33:481–517.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Katsanos A, Quaranta L, et al. Twenty-four hour efficacy of glaucoma medications. Prog Brain Res. 2015;221:297–318.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Hollo G, Haidich AB, et al. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy. J Ocul Pharmacol Ther. 2013;29:652–657.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Mikropoulos D, Dimopoulos AT, et al. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy. Br J Ophthalmol. 2008;92:1498–1502.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Boboridis KG, Kapis P, et al. 24-hour efficacy and ocular surface health with preservative-free tafluprost alone and in conjunction with preservative-free dorzolamide/timolol fixed combination in open-angle glaucoma patients insufficiently controlled with preserved latanoprost monotherapy. Adv Ther. 2017;34:221–235.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Topouzis F, Leliopoulou O, et al. 24-hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-angle glaucoma. Ophthalmology. 2006;113:761–765 e761.
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279.
   PubMed Web of Science ®Google Scholar
• Simbrinza™ (brinzolamide 1%/brimonidine tartrate ophthalmic suspension 0.2%). Full Prescribing Information. Novartis; 2013.
   Google Scholar
• Fang Y, Ling Z, Sun X. Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol. Drug Des Devel Ther. 2015;9:2617–2625.
   PubMed Web of Science ®Google Scholar
• Ganfort (timolol/bimatoprost). Summary of Product Characteristics. Allergan; 2011.
   Google Scholar
• Combigan (timolol maleate/brimonidine tartrate). Summary of Product Characteristics. Allergan; 2015.
   Google Scholar
• Combigan (brimonidine tartrate 0.2%/timolol maleate 0.5%/ophthalmic solution). Full Prescribing Information. Allergan; 2007.
   Google Scholar
• Soriatane® (acitretin). Full Prescribing Information. Research Triangle Park (NC): Stiefel Laboratories, Inc.; 2014.
   Google Scholar
• AZARGA® (brinzolamide 1%/timolol 0.5% fixed combination). Summary of Product Characteristics. Surrey (UK): Novartis Europharm Limited; 2013.
   Google Scholar
• Cosopt (dorzolamide hydrochloride/timolol maleate). Full Prescribing Information. Lake Forest (IL): Akorn; 2015.
   Google Scholar
• Cosopt (dorzolamide hydrochloride/timolol maleate). Summary of Product Characteristics. Santen UK Limited; 2018.
   Google Scholar
• Xalacom (Iatanoprost/timolol). Full Prescribing Information. Canada: Pfizer; 2017.
   Google Scholar
• Xalacom (Iatanoprost/timolol). Summary of Product Characteristics. Pfizer Limited; 2018.
   Google Scholar
• Lerner SF, Park KH, Hubatsch DA, et al. Efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination for the treatment of primary open-angle glaucoma or ocular hypertension inadequately controlled with beta-blocker monotherapy. J Ophthalmol. 2017;2017:1917570.
   PubMed Web of Science ®Google Scholar